Helping people lead fuller, richer, more productive lives
DiaMedica Therapeutics is a publicly traded, clinical-stage biopharmaceutical company. We are listed in Canada on the TSX Venture Exchange under the symbol "DMA" and trade in the United States on the OTCQB under the symbol "DMCAF." For more information on our public listings or other investor information, please contact Mr. Paul Papi, Vice President, Business Development, by telephone at (763) 496-5151, or by email at firstname.lastname@example.org.
May is Stroke Awareness Month, and so we thought we would take the opportunity to share some quick facts about the most common type of stroke --- ischemic strokes.
According to the U.S. National Stroke Association, ischemic strokes account for about 87% of all strokes.
Ischemic stroke is characterized by the sudden loss of blood circulation to an area of the brain, resulting in a corresponding loss of neurologic function.
Ischemic stroke represents an area of tremendous unmet medical need. That’s why we at DiaMedica Therapeutics are focused on advancing our clinical compound, DM199 – a synthetic KLK1 protein being developed to treat ischemic stroke patients in China as an improved product over the urine-sourced KLK1 protein currently used there. DiaMedica also intends to seek worldwide approval for DM199 as a novel therapy for acute ischemic stroke. We believe that DM199 may one day fill a large unmet need for stroke patients who cannot receive tPA, benefiting millions of people around the world who currently have limited treatment options.
Learn more about ischemic stroke on our website at http://www.diamedica.com/product-candidates/dm199-acute-ischemic-stroke and on the National Stroke Association’s website at www.stroke.org.
We are excited to welcome you to the DiaMedica Blog. We intend to use this space to help you get to know us better – by providing more insight into the latest developments in our business – and to create more awareness for the conditions we treat. Our mission is helping people lead fuller, richer, more productive lives. Our focus is on neurological and kidney diseases.
This is a defining time for DiaMedica Therapeutics and we are thrilled to have you as a shareholder and witness as we advance our therapeutic platform.
Last December, we completed Part A of our bridging clinical study. We are delighted to have identified a dose of DM199 (synthetic KLK1) that could provide sustained therapeutic levels of DM199 and corresponding pharmacodynamic activity that is comparable to the approved human urinary KLK1 protein treatment (the “reference drug”) for acute ischemic stroke in Asia. We estimate that over 200,000 patients are treated each year with porcine and human urinary derived forms of the KLK1 protein in Asia with total estimated sales of over $200 million U.S. for the treatment of kidney disease and stroke in light of all the challenges of sourcing impure protein.
In March of this year, we completed Part B of our bridging clinical study and reported an improved subcutaneous dose of DM199 producing sustained plasma levels superior to the reference drug. We plan to use the results of this study to guide Phase II dosing in upcoming clinical trials.
Stay tuned for more news on our strategic direction and milestones as we continue to pursue our mission and advance the clinical development of DM199 and the rest of our pipeline. Subscribe to our RSS Feed for future blog posts and follow us on Twitter.
Two Carlson Parkway
Minneapolis, MN 55447